1h Free Analyst Time
The Nucleic Acid-Based Drugs Market grew from USD 4.76 billion in 2023 to USD 5.46 billion in 2024. It is expected to continue growing at a CAGR of 15.09%, reaching USD 12.74 billion by 2030. Speak directly to the analyst to clarify any post sales queries you may have.
Nucleic acid-based drugs are a class of therapeutics that utilize sequences of nucleic acids to modulate gene expression and treat various ailments. Their scope extends across several therapeutic areas, including oncology, cardiovascular diseases, and rare genetic disorders. This class of drugs is necessary as it offers targeted treatment options with potentially fewer side effects compared to traditional small molecule drugs, harnessing the specificity of nucleic acid interactions, such as RNA interference and antisense oligonucleotides. They find applications in personalized medicine, providing tailored therapies based on individual genetic profiles, and serve a critical role in advancing next-generation therapies. The end-use scope includes clinical treatments, academic research, and biotechnological applications, where they are key tools for experimental studies and drug development.
The nucleic acid-based drugs market is driven by factors such as advancements in genetic engineering, increasing prevalence of genetic disorders, and the growing interest of pharmaceutical companies in personalized medicine. Recent breakthroughs in CRISPR-Cas9 technology and RNA-based therapies have unlocked new potential opportunities. To capitalize on these, companies should invest in research collaborations and intellectual property acquisition to enhance product offerings and leverage cutting-edge technologies. However, market growth is hindered by limitations including high development costs, regulatory challenges, and concerns over delivery mechanisms and off-target effects. Addressing these issues will require continued innovation in delivery systems and comprehensive regulatory strategies to ensure safety and efficacy.
Areas ripe for innovation include novel delivery systems such as lipid nanoparticles and exosome-based carriers, improving the stability and specificity of nucleic acid drugs. Expanding research into mRNA vaccines and gene-editing technologies could also yield considerable growth and diversification opportunities. The nature of the market is highly dynamic, with intense competition and fast-paced technological advancements necessitating agile and strategic foresight from industry stakeholders to maintain a leading edge. As the field evolves, strategic partnerships and continuous innovation will be crucial in overcoming existing challenges and achieving sustainable growth.
Understanding Market Dynamics in the Nucleic Acid-Based Drugs Market
The Nucleic Acid-Based Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.- Market Drivers
- Growing prevalence of chronic diseases across the globe
- Rising awareness and acceptance of personalized medicine
- Market Restraints
- High costs of nucleic acid-based therapies
- Market Opportunities
- Expanding applications of nucleic acid-based drugs in treating rare genetic disorders
- Evolving collaboration between pharmaceutical companies and biotechnology firms
- Market Challenges
- Limitations in ensuring the stability and delivery of nucleic acid-based drugs
Exploring Porter’s Five Forces for the Nucleic Acid-Based Drugs Market
Porter’s Five Forces framework further strengthens the insights of the Nucleic Acid-Based Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.Applying PESTLE Analysis to the Nucleic Acid-Based Drugs Market
External macro-environmental factors deeply influence the performance of the Nucleic Acid-Based Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.Analyzing Market Share in the Nucleic Acid-Based Drugs Market
The Nucleic Acid-Based Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.Evaluating Vendor Success with the FPNV Positioning Matrix in the Nucleic Acid-Based Drugs Market
The Nucleic Acid-Based Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.Strategic Recommendations for Success in the Nucleic Acid-Based Drugs Market
The Nucleic Acid-Based Drugs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.Key Company Profiles
The report delves into recent significant developments in the Nucleic Acid-Based Drugs Market, highlighting leading vendors and their innovative profiles. These include Alnylam Pharmaceuticals, Inc., Arcturus Therapeutics Holdings Inc., Arrowhead Pharmaceuticals, Inc., Beam Therapeutics Inc., BioMarin Pharmaceutical Inc., Bluebird Bio, Inc., CRISPR Therapeutics AG, CureVac N.V., Dicerna Pharmaceuticals, Inc., Dynavax Technologies Corporation, Editas Medicine, Inc., Evotec SE, Generation Bio Co., Ionis Pharmaceuticals, Inc., Moderna, Inc., ProQR Therapeutics N.V., Sangamo Therapeutics, Inc, Sarepta Therapeutics, Inc., Senti Biosciences, Inc., Silence Therapeutics Plc, Stoke Therapeutics, Inc., Translate Bio, Inc. by Sanofi SA, Voyager Therapeutics, Inc., and Wave Life Sciences Ltd..Market Segmentation & Coverage
This research report categorizes the Nucleic Acid-Based Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:- Nucleic Acid Type
- DNA-based Drugs
- RNA-based Drugs
- Drug Type
- Long-Chain Nucleic Acid Drugs
- Short-Chain Nucleic Acid Drugs
- Method of Delivery
- Localized Delivery
- Systemic Delivery
- Therapeutic Application
- Cardiovascular Diseases
- Infectious Diseases
- Neurological Disorders
- Oncology
- Rare & Genetic Disorders
- End-User
- Biopharmaceutical Companies
- Hospitals & Clinics
- Research Organizations
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
The report provides a detailed overview of the market, exploring several key areas:
- Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
- Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
- Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
- Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
- Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.
Additionally, the report addresses key questions to assist stakeholders in making informed decisions:
- What is the current size of the market, and how is it expected to grow?
- Which products, segments, and regions present the most attractive investment opportunities?
- What are the prevailing technology trends and regulatory factors influencing the market?
- How do top vendors rank regarding market share and competitive positioning?
- What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?
Table of Contents
1. Preface1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing prevalence of chronic diseases across the globe
5.1.1.2. Rising awareness and acceptance of personalized medicine
5.1.2. Restraints
5.1.2.1. High costs of nucleic acid-based therapies
5.1.3. Opportunities
5.1.3.1. Expanding applications of nucleic acid-based drugs in treating rare genetic disorders
5.1.3.2. Evolving collaboration between pharmaceutical companies and biotechnology firms
5.1.4. Challenges
5.1.4.1. Limitations in ensuring the stability and delivery of nucleic acid-based drugs
5.2. Market Segmentation Analysis
5.2.1. Nucleic Acid Type: Emerging application of RNA-based drugs owing to specificity and efficiency in targeting genetic material
5.2.2. Therapeutic Application: Diverse applications of nucleic acid-based drugs in neurological disorders
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Nucleic Acid-Based Drugs Market, by Nucleic Acid Type
6.1. Introduction
6.2. DNA-based Drugs
6.3. RNA-based Drugs
7. Nucleic Acid-Based Drugs Market, by Drug Type
7.1. Introduction
7.2. Long-Chain Nucleic Acid Drugs
7.3. Short-Chain Nucleic Acid Drugs
8. Nucleic Acid-Based Drugs Market, by Method of Delivery
8.1. Introduction
8.2. Localized Delivery
8.3. Systemic Delivery
9. Nucleic Acid-Based Drugs Market, by Therapeutic Application
9.1. Introduction
9.2. Cardiovascular Diseases
9.3. Infectious Diseases
9.4. Neurological Disorders
9.5. Oncology
9.6. Rare & Genetic Disorders
10. Nucleic Acid-Based Drugs Market, by End-User
10.1. Introduction
10.2. Biopharmaceutical Companies
10.3. Hospitals & Clinics
10.4. Research Organizations
11. Americas Nucleic Acid-Based Drugs Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Nucleic Acid-Based Drugs Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Nucleic Acid-Based Drugs Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.3.1. GlaxoSmithKline PLC acquired Elsie Biotechnologies, LLC for USD 50 Million in a strategic move to boost nucleic acid drug development
14.3.2. Waters Corporation introduced advanced SEC columns to accelerate gene-based drug development
14.3.3. Asahi Kasei Bioprocess and Axolabs GmbH partner to accelerate the development of innovative gene-based therapies
14.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. NUCLEIC ACID-BASED DRUGS MARKET RESEARCH PROCESS
FIGURE 2. NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2023 VS 2030 (%)
FIGURE 11. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2030 (%)
FIGURE 13. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 15. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. NUCLEIC ACID-BASED DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. NUCLEIC ACID-BASED DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. NUCLEIC ACID-BASED DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. NUCLEIC ACID-BASED DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DNA-BASED DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA-BASED DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY LONG-CHAIN NUCLEIC ACID DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT-CHAIN NUCLEIC ACID DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY LOCALIZED DELIVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SYSTEMIC DELIVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RARE & GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 42. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 43. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 44. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 45. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 46. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 47. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 48. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 49. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 50. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 51. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 58. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 59. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 60. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 61. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 64. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 65. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 66. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 67. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 68. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 69. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 70. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 71. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 72. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 73. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 74. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 75. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 76. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 77. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 78. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 79. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 80. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 81. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 82. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 83. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 84. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 85. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 86. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 87. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 88. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 89. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 90. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 91. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 92. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 93. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 94. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 95. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 96. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 97. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 98. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 99. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 100. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 101. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 102. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 103. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 104. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 105. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 106. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 107. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 108. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 109. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 110. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 111. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 112. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 113. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 114. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 115. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 116. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 117. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 118. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 119. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 120. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 121. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 122. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 123. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 130. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 131. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 132. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 133. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 134. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 135. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 136. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 137. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 138. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 139. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 140. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 141. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 142. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 143. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 144. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 145. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 146. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 147. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 148. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 149. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 150. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 151. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 152. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 153. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 154. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 155. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 156. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 157. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 158. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 159. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 160. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 161. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 162. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 163. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 164. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 165. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 166. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 167. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 168. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 169. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 170. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 171. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 172. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 173. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 174. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 175. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 176. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 177. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 178. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 179. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 180. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 181. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 182. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 183. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 184. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 185. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 186. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 187. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 188. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 189. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 205. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 206. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 207. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 208. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 209. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 210. SWEDEN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 211. SWEDEN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 212. SWEDEN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 213. SWEDEN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 214. SWEDEN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 215. SWITZERLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 216. SWITZERLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 217. SWITZERLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 218. SWITZERLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 219. SWITZERLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 220. TURKEY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 221. TURKEY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 222. TURKEY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 223. TURKEY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 224. TURKEY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 230. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 232. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METHOD OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 234. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 235. NUCLEIC ACID-BASED DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 236. NUCLEIC ACID-BASED DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
Companies Mentioned
The leading players in the Nucleic Acid-Based Drugs market, which are profiled in this report, include:- Alnylam Pharmaceuticals, Inc.
- Arcturus Therapeutics Holdings Inc.
- Arrowhead Pharmaceuticals, Inc.
- Beam Therapeutics Inc.
- BioMarin Pharmaceutical Inc.
- Bluebird Bio, Inc.
- CRISPR Therapeutics AG
- CureVac N.V.
- Dicerna Pharmaceuticals, Inc.
- Dynavax Technologies Corporation
- Editas Medicine, Inc.
- Evotec SE
- Generation Bio Co.
- Ionis Pharmaceuticals, Inc.
- Moderna, Inc.
- ProQR Therapeutics N.V.
- Sangamo Therapeutics, Inc
- Sarepta Therapeutics, Inc.
- Senti Biosciences, Inc.
- Silence Therapeutics Plc
- Stoke Therapeutics, Inc.
- Translate Bio, Inc. by Sanofi SA
- Voyager Therapeutics, Inc.
- Wave Life Sciences Ltd.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 195 |
| Published | October 2024 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 5.46 Billion |
| Forecasted Market Value ( USD | $ 12.74 Billion |
| Compound Annual Growth Rate | 15.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 24 |
